Reduced CD34+ Stem Cells Predicts CV Outcome in T2DM

Share this content:
Reduced CD34<sup>&#43;</sup> Stem Cells Predicts CV Outcome in T2DM
Reduced CD34+ Stem Cells Predicts CV Outcome in T2DM

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Reduced baseline levels of circulating CD34+ stem cells predict adverse cardiovascular outcomes for patients with type 2 diabetes, according to a study published online Nov. 4 in Diabetes Care.

Gian Paolo Fadini, M.D., Ph.D., from the University of Padova in Italy, and colleagues monitored a cohort of 187 patients with type 2 diabetes for a median of 6.1 years. Six stem/progenitor cell phenotypes were measured in peripheral blood at baseline, based on expression of CD34, CD133, and KDR.

The researchers found that the primary outcome of time to a first cardiovascular event plus hospitalization for cardiovascular causes occurred in 48 patients (4.5/100 patient-years). Significantly lower CD34+ and CD34+CD133+ cells were seen in patients with versus those without incident cardiovascular events. The rates of cardiovascular events were higher in patients with below median levels of CD34+ and CD34+CD133+. Reduced CD34+ and CD34+CD133+ cell count independently predicted future events in hazard regression analyses (hazard ratios, 2.21 and 2.98, respectively). C statistics, continuous net reclassification improvement, and/or integrated discrimination index were improved with addition of the CD34+ cell count to the reference model or the U.K. Prospective Diabetes Study risk engine.

"In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem cells predicts adverse cardiovascular outcomes up to six years later and improves risk stratification," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »